Skip to main content
. Author manuscript; available in PMC: 2024 Oct 2.
Published in final edited form as: Mol Cancer Res. 2024 Apr 2;22(4):386–401. doi: 10.1158/1541-7786.MCR-23-0445

Fig. 7. AHCYL1 transcription in NRAS-mutated melanoma cells is regulated by transcription factor ATF2.

Fig. 7.

(A) TCGA database analysis of ATF2 mRNA levels in human skin cutaneous melanoma samples expressing NRAS mutant, BRAF mutant, or WT. Highlighted lines indicate dataset median. (B) ATF2 relative mRNA expression in human melanoma cell lines expressing mutated NRAS or mutated BRAF by RT-qPCR. (C) ATF2 protein expression in human melanoma cell lines expressing mutated NRAS or mutated BRAF by immunoblotting. (D) Relative ATF2 mRNA levels in human immortal melanocytes Mel-ST, exogenously expressed with mutated NRAS, mutated BRAF, or vector by RT-qPCR. (E) Relative AHCYL1 (left) and ATF2 (middle) mRNA levels after ATF2 knockout by RT-qPCR. Cell proliferation (right) of human melanoma cells expressing NRAS mutant. (F) Relative AHCYL1 (left) and ATF2 (middle) mRNA levels after ATF2 knockout by RT-qPCR. Cell proliferation (right) of human melanoma cells expressing BRAF mutant. (G) Proposed working model. Error bars indicate means ± SD (n ≥ 3). p-values were calculated using two-tailed, unpaired Student’s t-test (ns, not significant; *, p≤0.05; **, p≤0.01; ***, p≤0.001).